Promising biomarker in epithelial cancer diagnosis and prognosis
It is worth mentioning that HE4 is not only a possible prognostic marker, with recent studies showing that it is also a promising serum and tissue biomarker for diagnosis in lung cancer, ovarian carcinoma, and endometrial cancer, as well as a differential marker for identification of ovarian cancer from benign gynecologic disease. 2, 3 It is emerging as a clinically significant biomarker in ovarian cancer.
Systematic review and meta-analysis guidelines and protocol registration
Furthermore, the authors have not specified the following of any systematic review and meta-analysis guidelines. These guidelines (such as PRISMA, JBI, and MOOSE) exist to homogenize and standardize systematic reviews and meta-analysis to inform and benefit future research, which is one of the primary impetus behind conducting of a study, which cumulates and analyzes previous existing literature. It is also suggested that the protocols used for performing a systematic review and meta-analysis are registered in the PROSPERO database, which allows peers to replicate the type of study undertaken as well as provide insight on the process behind the study.
Publication bias of the included studies
It is also worth noting that the evaluation publication bias consists of a few key modules to evaluate the bias of the included studies. Although the Begg's and Eggers' test alongside the funnel plots were used for assessing publication bias in Dai et 
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Jayaraj and Kumarasamy study, another key assessment that is worth including is the "Duval and Tweedie's trim and fill" method. This method is an essential module that may be used to impute missing small studies with large effect size to be dispersed equally on either side of the overall effect. 4 
Survival endpoints
As this study considers disease-free survival (DFS) as an endpoint for its meta-analysis, an evaluation of recurrence rates is also possible as patients that do not fall under DFS would have suffered relapses. This additional analysis is a natural extension of the data already being presented, and might serve to help future research in this field.
the pooled effect size of cancer patients' survival Additionally, the pooled HRs for the subgroups of Asian (2.62) and lung cancer (2.31) as well as for DFS of all studies (2.50) are relatively high when compared to other subgroup cohorts and survival endpoints, as they indicate that the probability of death is over twice as likely for the patients expressing HE4 as compared to patients not expressing HE4 in cancer. These marked differences in HR values between different cancers and different populations require further evaluation and analysis.
threshold effects: correlation between the ranks of effect sizes and the ranks of their variances
It is also notable that c 2 and I 2 values may not be sufficient as statistical parameters as they do not consider the threshold effect. In random-effects meta-analysis, it may be useful to also include the t 2 parameter for estimating variance or heterogeneity between the effects for test accuracy, as the t 2 parameter does consider the threshold effect. 5 These points mentioned above are to address improvements that could benefit Dai et al's study and help elevate its impact on future research. These points should also help guide future similar systematic reviews and meta-analyses.
Dear editor
We thank Dr Rama Jayaraj and Chellan Kumarasamy for their interest and comments. They came up with several valuable points that improved our meta-analysis. 1 As they mentioned, recent studies 2, 3 showed that HE4 was a promising serum and tissue biomarker for diagnosis in lung cancer, ovarian carcinoma, and endometrial cancer, but its prognostic value remains controversial. Therefore, this is why we did this study to accurately assess the prognostic value of HE4 expression in cancer patients.
Our meta-analysis is based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. 4 However, the review protocol was not registered in the PROSPERO database, which is an oversight of our work.
In terms of publication bias of the included studies, we think that the use of Begg's and Eggers' test alongside the funnel plots was enough to assess the publication bias. What's more important, the "Duval and Tweedie's trim and fill" method 5 was currently controversial in assessing publication bias. So we did not use this method at that time. Now we can provide the result here. The combined HR and 95% CI of filled meta-analysis is 1.645 and 1.352-2.002 (randomeffects model) (Figure 1) .
We would like to further explore some subgroups or more survival endpoints, such as Asian, lung cancer, disease-free survival, and the other you mentioned. But due to the lack of relevant researches, it cannot be achieved. So, more studies are needed to clarify these questions.
As mentioned by Dr Rama Jayaraj and Chellan Kumarasamy, in random-effects meta-analysis, it was more accurate to use t 2 parameter for estimating heterogeneity, when compared with c 2 and I 2 values. Nevertheless, there is no difference between the two results in our study.
Based on the above, despite those limitations mentioned above, the final conclusion was still accurate. Overall, we really appreciate the comments from Dr Rama Jayaraj and Chellan Kumarasamy.
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